Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval

 
• By Bridget Silverman
Wait sign (source: shutterstock)
• Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers